Learn the latest on the dementia research and treatment landscape, as ADI invites a guest panel to shed light on this rapidly evolving sector. Join us for our webinar, Dementia Research In Action: from trials to treatments at 1pm GMT on 13 November.
In 2024, ADI hosted its inaugural End of Year Forecast, which marked the new era of dementia treatments by holding a livestreamed conversation with Professor Jeff Cummings, who shared his insights on the current pipeline of 127 drug treatments.
This year, with a growing number of drug treatments currently in trials for Alzheimer’s disease, and many others addressing conditions such as Lewy Body Dementia and frontotemporal dementia, ADI welcomes our global audience to join us for this webinar, as we discuss new developments in the research field and share the insights of those involved in designing, running and participating in clinical trials.
We will look at the journey of new treatments, from regulator approval to clinic implementation, and explore the latest innovations in research. This webinar will also welcome insights from a person living with dementia who will discuss their involvement in treatment research and trials. This webinar will also welcome insights from a person living with dementia who will discuss their involvement in treatment research and trials.
The panel discussion, guided by ADI CEO Paola Barbarino, will cover topics that are crucial in the conducting of research towards treatments, such as:
- Challenges of recruiting and running clinical trials for experimental dementia therapies;
- Hopes for the future for hosting clinical trials in lower resource settings;
- What happens after a therapy receives regulatory approval? What steps are needed to ensure that health systems are ready to ensure access to the new treatment?
- How innovative approaches are beginning to show success in the treatment of Alzheimer’s and dementia.
This webinar will be hosted by ADI CEO, Paola Barbarino, and will welcome the following speakers:
- Bill Yeates, Board member and dementia advocate, ADI
- Marco Lyons, Global Medical Lead, Alzheimer’s Disease, Roche
- Kay Bhothinard, Senior Director & Global Lead, Alzheimer’s Disease Diagnostics, Eisai
- Sarah Bottomley, Director, Patient Recruitment, Parexel
AI translations will be available in over 67 languages
Including Afrikaans, Albanian, Arabic, Bengali, Cantonese, Chinese (Simplified), Chinese (Traditional), Croatian, Czech, Danish, Dutch, English, Estonian, Finnish, French, German, Greek, Gujarati, Hebrew, Hindi, Hungarian, Indonesian (Bahasa), Irish, Italian, Japanese, Korean, Malay, Norwegian, Persian, Polish, Portuguese, Punjabi, Romanian, Russian, Serbian, Slovak, Spanish, Swahili, Swedish, Tagalog, Tamil, Thai, Turkish, Ukrainian, Urdu, Vietnamese and Welsh.